EP1003500A4 - Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury - Google Patents

Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury

Info

Publication number: EP1003500A4
Authority: EP; European Patent Office
Prior art keywords: nitric oxide; vascular injury; lesion formation; intramural delivery; oxide enhancer
Prior art date: 1996-08-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP97938163A

Other languages

German (de)

French (fr)

Other versions

EP1003500A1 (en

Inventor

John P Cooke

Sverin Schwarzacher

Tai T Lim

Alan C Yeung

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Leland Stanford Junior University

Original Assignee

Leland Stanford Junior University

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-08-12

Filing date

1997-08-07

Publication date

2004-06-23

1996-08-12 Priority claimed from US08/695,792 external-priority patent/US5852058A/en

1997-08-07 Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University

2000-05-31 Publication of EP1003500A1 publication Critical patent/EP1003500A1/en

2004-06-23 Publication of EP1003500A4 publication Critical patent/EP1003500A4/en

Status Withdrawn legal-status Critical Current

Links

MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 title 2
208000024248 Vascular System injury Diseases 0.000 title 1
208000012339 Vascular injury Diseases 0.000 title 1
230000015572 biosynthetic process Effects 0.000 title 1
239000003623 enhancer Substances 0.000 title 1
230000002401 inhibitory effect Effects 0.000 title 1
230000003902 lesion Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Polymers & Plastics (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Cardiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Heart & Thoracic Surgery (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Vascular Medicine (AREA)
Nutrition Science (AREA)
Food Science & Technology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

EP97938163A 1996-08-12 1997-08-07 Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury Withdrawn EP1003500A4 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US695792		1996-08-12
US08/695,792 US5852058A (en)	1993-06-11	1996-08-12	Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury
PCT/US1997/013905 WO1998006389A1 (en)	1996-08-12	1997-08-07	Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury

Publications (2)

Publication Number	Publication Date
EP1003500A1 EP1003500A1 (en)	2000-05-31
EP1003500A4 true EP1003500A4 (en)	2004-06-23

Family

ID=24794481

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP97938163A Withdrawn EP1003500A4 (en)	1996-08-12	1997-08-07	Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury

Country Status (4)

Country	Link
EP (1)	EP1003500A4 (en)
JP (1)	JP2000516612A (en)
DE (1)	DE69637676D1 (en)
WO (1)	WO1998006389A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6587718B2 (en)	1999-10-08	2003-07-01	Scimed Life Systems, Inc.	Iontophoretic delivery to heart tissue
US6706274B2 (en)	2001-01-18	2004-03-16	Scimed Life Systems, Inc.	Differential delivery of nitric oxide
US8506617B1 (en)	2002-06-21	2013-08-13	Advanced Cardiovascular Systems, Inc.	Micronized peptide coated stent
WO2006128121A2 (en)	2005-05-27	2006-11-30	The University Of North Carolina At Chapel Hill	Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
EP2467173B8 (en)	2009-08-21	2019-06-19	Novan, Inc.	Wound dressings, methods of using the same and methods of forming the same
ES2958410T3 (en)	2009-08-21	2024-02-08	Novan Inc	Topical gels
US8591876B2 (en)	2010-12-15	2013-11-26	Novan, Inc.	Methods of decreasing sebum production in the skin
WO2012118829A2 (en)	2011-02-28	2012-09-07	Novan, Inc.	Tertiary s-nitrosothiol-modified nitricoxide-releasing xerogels and methods of using the same

Citations (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0483614A1 (en) *	1990-10-30	1992-05-06	Clintec Nutrition Company	Use of amino acids for the protection of and metabolic recovery of ischemic cardiac tissue
US5171217A (en) *	1991-02-28	1992-12-15	Indiana University Foundation	Method for delivery of smooth muscle cell inhibitors
WO1995005866A1 (en) *	1993-08-27	1995-03-02	Cortrak Medical Inc.	Simultaneous angioplasty and drug delivery
WO1995024898A1 (en) *	1994-03-17	1995-09-21	Comedicus, Incorporated	Complexes of nitric oxide with cardiovascular amines as dual acting cardiovascular agents
WO1996000112A1 (en) *	1994-06-23	1996-01-04	Cormedics Corp.	Vascular treatment method and apparatus
WO1997016983A1 (en) *	1995-11-09	1997-05-15	The Board Of Trustees Of The Leland Stanford Junior University	Enhancement of vascular function by modulation of endogenous nitric oxide production or activity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5236413B1 (en) *	1990-05-07	1996-06-18	Andrew J Feiring	Method and apparatus for inducing the permeation of medication into internal tissue
US5499971A (en) *	1990-06-15	1996-03-19	Cortrak Medical, Inc.	Method for iontophoretically delivering drug adjacent to a heart
US5428070A (en) *	1993-06-11	1995-06-27	The Board Of Trustees Of The Leland Stanford Junior University	Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production of activity

1996
- 1996-10-24 DE DE69637676T patent/DE69637676D1/en not_active Expired - Fee Related
1997
- 1997-08-07 WO PCT/US1997/013905 patent/WO1998006389A1/en active Application Filing
- 1997-08-07 JP JP10509860A patent/JP2000516612A/en active Pending
- 1997-08-07 EP EP97938163A patent/EP1003500A4/en not_active Withdrawn

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0483614A1 (en) *	1990-10-30	1992-05-06	Clintec Nutrition Company	Use of amino acids for the protection of and metabolic recovery of ischemic cardiac tissue
US5171217A (en) *	1991-02-28	1992-12-15	Indiana University Foundation	Method for delivery of smooth muscle cell inhibitors
WO1995005866A1 (en) *	1993-08-27	1995-03-02	Cortrak Medical Inc.	Simultaneous angioplasty and drug delivery
WO1995024898A1 (en) *	1994-03-17	1995-09-21	Comedicus, Incorporated	Complexes of nitric oxide with cardiovascular amines as dual acting cardiovascular agents
WO1996000112A1 (en) *	1994-06-23	1996-01-04	Cormedics Corp.	Vascular treatment method and apparatus
WO1997016983A1 (en) *	1995-11-09	1997-05-15	The Board Of Trustees Of The Leland Stanford Junior University	Enhancement of vascular function by modulation of endogenous nitric oxide production or activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9806389A1 *

Also Published As

Publication number	Publication date
WO1998006389A1 (en)	1998-02-19
JP2000516612A (en)	2000-12-12
DE69637676D1 (en)	2008-10-23
EP1003500A1 (en)	2000-05-31

Legal Events

Date	Code	Title	Description
2000-04-14	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2000-05-31	17P	Request for examination filed	Effective date: 19990310
2000-05-31	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
2004-06-23	A4	Supplementary search report drawn up and despatched	Effective date: 20040507
2004-06-23	RIC1	Information provided on ipc code assigned before grant	Ipc: 7A 61N 1/30 B Ipc: 7A 61M 29/02 B Ipc: 7A 61M 25/10 B Ipc: 7A 61K 31/195 A
2007-01-17	17Q	First examination report despatched	Effective date: 20061219
2009-08-28	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2009-09-30	18D	Application deemed to be withdrawn	Effective date: 20090408

Publication	Publication Date	Title
EP1178727A4 (en)	2006-07-26	A therapeutic mixture useful in inhibiting lesion formation after vascular injury
ZA974041B (en)	1998-11-09	Preparation and prevention of fibrotic lesions
EP1080103A4 (en)	2003-07-02	Compositions and methods for non-parenteral delivery of oligonucleotides
IL128488A0 (en)	2000-01-31	Inhibiting undesirable taste in oral composition
HUP0100815A3 (en)	2002-11-28	Pharmaceutical for treatment of neurological and neuropsychiatric disorders
EP1080226A4 (en)	2004-04-21	Compositions and methods for topical delivery of oligonucleotides
ZA977902B (en)	1998-08-11	Fatty acid treatment
GB0015235D0 (en)	2000-08-16	Compositions for the treatment of skin and anorectal conditions
EP1015014A4 (en)	2005-01-05	Methods and compositions for inhibiting angiogenesis
IL129089A0 (en)	2000-02-17	New derivatives from piperidine-keto acid their preparation and use
IL130150A0 (en)	2001-03-19	Fluoroether compositions and methods for inhibiting their degradation in the presence of a lewis acid
EP0960191A4 (en)	2003-07-23	Compositions and methods for use of defensin
PL328074A1 (en)	1999-01-04	Therapeutical method and pharmaceutic composition
EP1003500A4 (en)	2004-06-23	Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury
EP0675119A3 (en)	1997-01-08	Preparation of substantially anhydrous propylene oxide.
GB9611180D0 (en)	1996-07-31	Treatment of vascular lesions
PL331263A1 (en)	1999-07-05	Derivatives of glyoxylic acid
HUP0002012A3 (en)	2002-09-30	Use of desferriexochelin for the preparation of pharmaceutical compositions treating atherosclerosis and vascular injury
IL131666A0 (en)	2001-01-28	Novel carboxylic acid derivatives their preparation and use in treating cancer
GB9621373D0 (en)	1996-12-04	Fatty acid treatment
HUP0001097A3 (en)	2003-05-28	Use of comt inhibitors for the manufacture of a medicament for the prevention of diabetic vascular dysfunctions
IL130402A0 (en)	2000-06-01	Flavour enhancer
GB2318789B (en)	2001-03-21	Carboxylic acid derivatives,method of manufacturing the same and therapeutic agents containing these compounds
EP1030681A4 (en)	2001-07-04	Method and compositions for inhibiting angiogenesis and treating cancer
EP0974364A4 (en)	2000-12-20	Method of inhibiting drug precipitation